Antoine DOSSIER

Dr. Antoine DOSSIER


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Toxins
Verified
Journal Article
Open access
PDF file
BTBenoit Travert
Benoit Travert
CRCédric Rafat
Cédric Rafat
PMPatricia Mariani
Patricia Mariani
ACAurélie Cointe
Aurélie Cointe
ADAntoine DOSSIER
Antoine DOSSIER
AJAdrien JOSEPH
Adrien JOSEPH
Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is a form of thrombotic microangiopathy secondary to an infection by an enterohemorrhagic E. coli. Historically considered a pediatric disease, its presentation has been described as typical, with bloody diarrhea at the forefront. However, in adults, the clinical presentation is more diverse and makes the early diagnosis hazardous. In this review, we review the epidemiology, most important outbreaks, physiopathology, clinical presentation and prognosis of STEC-HUS, focusing on the differential features between pediatric and adult disease. We show that the clinical presentation of STEC-HUS in adults is far from typical and marked by the prevalence of neurological symptoms and a poorer prognosis. Of note, we highlight knowledge gaps and the need for studies dedicated to adult patients. The differences between pediatric and adult patients have implications for the treatment of this disease, which remains a public health threat and lack a specific treatment.

Verified
Journal Article
Open access
PDF file
SCSimon CHAUVEAU
Simon CHAUVEAU
FJFlorence Jeny
Florence Jeny
MMMarie-Emeline Montagne
Marie-Emeline Montagne
RTRola Abou Taam
Rola Abou Taam
VHVéronique Houdouin
Véronique Houdouin
F(for the French Sarcoidosis Group (GSF)
for the French Sarcoidosis Group (GSF)
(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoidosis (≤15-year-old) who completed at least a three-year follow-up in French expert centers were included. Clinical information at presentation and outcome in adulthood were studied. (3) Results: A total of 52 patients were included (34 prospectively in childhood and 18 retrospectively in adulthood), with a mean age of 12 (±2.7) at diagnosis. The median duration time of follow-up was 11.5 years (range 3–44.5). Relapses mostly occurred during treatment decrease (84.5%), others within the three years after treatment interruption (9.1%), and rarely when the disease was stable for more than three years (6.4%). Sarcoidosis was severe in 11 (21.2%) in adulthood. Patients received a high corticosteroid cumulative dose (median 17,900 mg) for a median duration of five years (range 0–32), resulting in mostly mild (18; 35.3%) and rarely severe (2; 3.8%) adverse events. (4) Conclusions: Pediatric-onset sarcoidosis needed a long-term treatment in almost half of the patients. Around one fifth of pediatric-onset sarcoidosis patients had severe sarcoidosis consequences in adulthood.

14 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MHMarie-Cécile Henry-Feugeas
Marie-Cécile Henry-Feugeas
AGAugustin Gaudemer
Augustin Gaudemer
XLXavier Lescure
Xavier Lescure
ADAntoine DOSSIER
Antoine DOSSIER
RSRomain Sonneville
Romain Sonneville
AKAntoine Khalil
Antoine Khalil
Summary: The pathogenesis of encephalopathy-associated Covid-19 is still unclear. Multimodal brain MRI in 25 Covid-19 patients with neurological symptoms revealed angiographic and brain perfusion changes suggesting an under-recognized dysregulated brain perfusion not identified by morphological neuroimaging alone. Endothelial dysfunction, a key pathomechanism of dysregulated brain perfusion, may contribute to central-nervous-system disturbances in Covid-19.